Suppr超能文献

多药耐药相关蛋白:一种与参与细胞毒性药物外排的P-糖蛋白不同的蛋白质。

Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.

作者信息

Barrand M A, Bagrij T, Neo S Y

机构信息

Department of Pharmacology, University of Cambridge.

出版信息

Gen Pharmacol. 1997 May;28(5):639-45. doi: 10.1016/s0306-3623(96)00284-4.

Abstract
  1. Multidrug resistance (MDR) is a phenomenon originally seen in cultured tumor cells that, following selection for resistance to a single anticancer agent, become resistant to a range of chemically diverse anticancer agents. These MDR cells show a decrease in intracellular drug accumulation due to active efflux by transporter proteins. The transporter best characterized is P-glycoprotein (Pgp). This protein has been identified in many cancers and has been the target for agents able to inhibit its action, thereby reversing resistance. 2. More recently, another transporter, multidrug resistance-associated protein (MRP) has been identified in a number of MDR human tumor cell lines that do not apparently express Pgp. The presence of MRP at the cell surface of these cells is associated with alterations in drug accumulation and distribution. 3. The gene-encoding MRP has been cloned and sequenced and shown by transfection studies to be able to confer resistance and changes in drug accumulation in sensitive tumor cells. The profile of anticancer drugs expelled in the presence of MRP is similar, but not identical, to that of Pgp. 4. MRP has been identified in a number of different types of cancers, but it is not yet clear to what extent it is involved with clinical resistance. Furthermore, resistance modulators useful against Pgp are less effective in reversing MRP-mediated resistance. 5. It is not fully understood how MRP brings about drug efflux, but it is clear that the underlying mechanisms are different from those responsible for Pgp-mediated drug efflux. In particular, glutathione (GSH) is required for the effective expulsion of the anticancer agents. 6. Unlike Pgp, MRP is able to transport metallic oxyanions and glutathione and other conjugates, including peptidyl leukotrienes. Agents that inhibit organic anion transport, such as probenecid, can block MRP activity. 7. Like Pgp, MRP is expressed not only in resistant tumor cells, but also in normal human tissues. These include the epithelial cells lining the airways and the gastrointestinal tract. In cells in normal tissues, MRP appears to be located within the cytoplasm, which may mean that it functions here in a manner slightly different to that in malignant cells. It is now also recognized in cells and tissues from other species, such as the rat and mouse.
摘要
  1. 多药耐药(MDR)是一种最初在培养的肿瘤细胞中发现的现象,即在选择对单一抗癌药物产生耐药性后,这些细胞会对一系列化学结构不同的抗癌药物产生耐药性。由于转运蛋白的主动外排作用,这些多药耐药细胞的细胞内药物积累减少。研究最充分的转运蛋白是P-糖蛋白(Pgp)。这种蛋白已在多种癌症中被鉴定出来,并且一直是能够抑制其作用从而逆转耐药性的药物的作用靶点。2. 最近,另一种转运蛋白——多药耐药相关蛋白(MRP)在一些明显不表达Pgp的多药耐药人类肿瘤细胞系中被鉴定出来。这些细胞表面存在MRP与药物积累和分布的改变有关。3. 编码MRP的基因已被克隆和测序,转染研究表明它能够使敏感肿瘤细胞产生耐药性并改变药物积累。在MRP存在的情况下排出的抗癌药物谱与Pgp相似,但不完全相同。4. MRP已在多种不同类型的癌症中被鉴定出来,但目前尚不清楚它在临床耐药中所涉及的程度。此外,对Pgp有效的耐药调节剂在逆转MRP介导的耐药性方面效果较差。5. 目前尚未完全了解MRP是如何导致药物外排的,但很明显其潜在机制与Pgp介导的药物外排机制不同。特别是,谷胱甘肽(GSH)是有效排出抗癌药物所必需的。6. 与Pgp不同,MRP能够转运金属氧阴离子、谷胱甘肽和其他共轭物,包括肽基白三烯。抑制有机阴离子转运的药物,如丙磺舒,能够阻断MRP的活性。7. 与Pgp一样,MRP不仅在耐药肿瘤细胞中表达,也在正常人体组织中表达。这些组织包括呼吸道和胃肠道的上皮细胞。在正常组织的细胞中,MRP似乎位于细胞质内,这可能意味着它在这里的功能与在恶性细胞中的功能略有不同。现在在大鼠和小鼠等其他物种的细胞和组织中也发现了MRP。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验